Finance

Lists
YAG:FRA
Atossa Therapeutics Inc
€2.10
+2.94%
(+0.060) 1D
Sep 3, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for YAG...
Open
€2.10
High
€2.10
Low
€2.10
Mkt. cap
25.25M
Avg. vol.
107.00
Volume
0.00
52-wk high
€6.75
52-wk low
€1.52
No. of employees
16
Open
€2.10
High
€2.10
Low
€2.10
Mkt. cap
25.25M
Avg. vol.
107.00
Volume
0.00
52-wk high
€6.75
52-wk low
€1.52
No. of employees
16
About Atossa Therapeutics Inc
CEOSteven C. Quay
Employees16
Founded2009
HeadquartersSeattle, Washington, United States
SectorBiotechnology
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
5.37M
6.16M
4.78M
4.90M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.88M
5.28M
5.09M
3.80M
Operating expense
9.25M
11.44M
9.87M
8.69M
Total operating expenses
9.25M
11.44M
9.87M
8.69M
Operating income
-9.25M
-11.44M
-9.87M
-8.69M
Other non operating income
-11.00K
57.00K
-28.00K
-24.00K
EBT including unusual items
-8.69M
-10.94M
-9.59M
-8.49M
EBT excluding unusual items
-8.69M
-10.94M
-9.59M
-8.49M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-8.69M
-10.94M
-9.59M
-8.49M
Net profit margin
-
-
-
-
Earnings per share
-1.05
-1.34
-1.11
-0.95
Interest and investment income
570.00K
442.00K
309.00K
227.00K
Interest expense
-
-
-
-
Net interest expenses
570.00K
442.00K
309.00K
227.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-9.25M
-11.43M
-9.87M
-8.69M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google apps